By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biolex Therapeutics 

158 Credle Street

Pittsboro  North Carolina  27312  U.S.A.
Phone: 919-542-9901 Fax: 919-542-9910



Company News
Biolex Therapeutics Execs Gone Before Filing for $38 Million Bankruptcy 7/9/2012 8:06:30 AM
Biolex Therapeutics Sells LEX System to Synthon and Initiates Sale of Locteron(R) 5/7/2012 8:47:49 AM
OctoPlus' Licensee Biolex Therapeutics Presents Phase IIb Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated With Locteron 3/31/2011 9:02:41 AM
OctoPlus' Licensee Biolex Therapeutics to Present Final Results of Locteron Phase IIb Study at EASL Conference 3/10/2011 9:55:20 AM
Biolex Therapeutics to Present Final Phase 2b Results at EASL for Locteron(R) Next-Generation Controlled-Release Interferon for HCV 3/10/2011 9:52:37 AM
Biolex Therapeutics Names Kurt Graves Executive Chairman as Company Prepares for Phase 3 Trials and Commercialization of Locteron(R) in Hepatitis C 11/9/2010 9:29:46 AM
OctoPlus' Licensee Biolex Therapeutics Presents Significant Tolerability Advantages of Locteron at AASLD Conference Today 11/1/2010 9:46:22 AM
Biolex Therapeutics Presents at AASLD Meeting Significant Tolerability Advantages of Locteron(R), Its Next-Generation Interferon for Hepatitis C 11/1/2010 9:30:04 AM
Biolex Therapeutics Announces Locteron(R) SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial 10/28/2010 6:40:43 AM
Biolex Therapeutics and Merial Broaden Collaboration 7/15/2010 12:44:28 PM